Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Valavaara

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Acta Oncologica (Stockholm, Sweden)|January 1, 1992
Interferon combined with irradiation in the treatment of operable head and neck carcinoma. A pilot studyR Valavaara, A E Kortekangas, E Nordman, et al.
European Journal of Radiology|July 1, 1995
Low-dose and conventional-dose high resolution CT of pulmonary changes in breast cancer patients treated by tangential field radiotherapyM L Majurin, R Valavaara, M Varpula, et al.
Anticancer Research|November 20, 2001
Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancerA Jukkola, R Bloigu, K Holli, et al.
Breast Cancer Research and Treatment|August 1, 1990
High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative studyT Hietanen, D Baltina, R Johansson, et al.
Oncology (Williston Park, N.Y.)|May 1, 1997
Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancerT Hietanen, T Hakala, D Baltina, et al.
European Radiology|May 2, 1998
Glomus tumor of the tracheaS K Koskinen, P T Niemi, T O Ekfors, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer GroupK Holli, R Valavaara, G Blanco, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
Treatment results of nasopharyngeal cancer--a nationwide survey from FinlandM Kajanti, M Flander, R Grenman, et al.
Journal of Steroid Biochemistry|June 22, 1990
Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communicationS Pyrhönen, R Valavaara, M Heikkinen, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1990
The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assayT Jaakkola, Y Q Ding, P Kellokumpu-Lehtinen, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Acta Oncologica (Stockholm, Sweden)|January 1, 1992
Interferon combined with irradiation in the treatment of operable head and neck carcinoma. A pilot studyR Valavaara, A E Kortekangas, E Nordman, et al.
European Journal of Radiology|July 1, 1995
Low-dose and conventional-dose high resolution CT of pulmonary changes in breast cancer patients treated by tangential field radiotherapyM L Majurin, R Valavaara, M Varpula, et al.
Anticancer Research|November 20, 2001
Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancerA Jukkola, R Bloigu, K Holli, et al.
Breast Cancer Research and Treatment|August 1, 1990
High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative studyT Hietanen, D Baltina, R Johansson, et al.
Oncology (Williston Park, N.Y.)|May 1, 1997
Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancerT Hietanen, T Hakala, D Baltina, et al.
European Radiology|May 2, 1998
Glomus tumor of the tracheaS K Koskinen, P T Niemi, T O Ekfors, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer GroupK Holli, R Valavaara, G Blanco, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
Treatment results of nasopharyngeal cancer--a nationwide survey from FinlandM Kajanti, M Flander, R Grenman, et al.
Journal of Steroid Biochemistry|June 22, 1990
Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communicationS Pyrhönen, R Valavaara, M Heikkinen, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1990
The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assayT Jaakkola, Y Q Ding, P Kellokumpu-Lehtinen, et al.
Pageof 3